Ftse Mib
35.390,52
-0,06%
DAX
18.704,42
-0,11%
S&P 500
5.300,54
0,06%
NASDAQ
16.681,40
-0,10%
Bitcoin
67.051,55
2,78%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Natera Inc (NTRA) Natera Inc (NTRA) Notizie

NTRA

Natera (NTRA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NTRA
DataOraFonteTitoloSimboloCompagnia
15/05/202422:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTRANatera Inc
11/05/202403:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
09/05/202422:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTRANatera Inc
09/05/202422:05Business WireNatera Reports First Quarter 2024 Financial ResultsNASDAQ:NTRANatera Inc
03/05/202414:00Business WireNew Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast CancerNASDAQ:NTRANatera Inc
01/05/202422:05Business WireNatera to Report its First Quarter 2024 Results on May 9NASDAQ:NTRANatera Inc
01/05/202413:00Business WireNatera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg ShortageNASDAQ:NTRANatera Inc
22/04/202414:00Business WireNatera Announces Significant Milestone with 200+ Peer-Reviewed PublicationsNASDAQ:NTRANatera Inc
11/04/202414:00Business WireNatera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney TransplantationNASDAQ:NTRANatera Inc
08/04/202414:00Business WireNatera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant RecipientsNASDAQ:NTRANatera Inc
05/04/202413:00Business WireNatera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder CancerNASDAQ:NTRANatera Inc
01/04/202414:00Business WireNatera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial CancerNASDAQ:NTRANatera Inc
18/03/202412:00Business WireNatera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal CancerNASDAQ:NTRANatera Inc
14/03/202413:00Business WireNew KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of DiseaseNASDAQ:NTRANatera Inc
12/03/202413:00Business WireNatera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast CancersNASDAQ:NTRANatera Inc
07/03/202414:00Business WireNatera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS PlanNASDAQ:NTRANatera Inc
29/02/202414:00Business WireNatera to Participate in March Investor ConferencesNASDAQ:NTRANatera Inc
28/02/202422:05Business WireNatera Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:NTRANatera Inc
27/02/202414:00Business WireNatera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure TestsNASDAQ:NTRANatera Inc
26/02/202413:00Business WireMedicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast CancerNASDAQ:NTRANatera Inc
20/02/202414:00Business WireNatera Announces Fourth Quarter and Fiscal 2023 Earnings Conference CallNASDAQ:NTRANatera Inc
05/02/202414:00Business WireNew Study Validates Signatera™ in Endometrial CancerNASDAQ:NTRANatera Inc
31/01/202403:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NTRANatera Inc
30/01/202413:00Business WireNew Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung CancerNASDAQ:NTRANatera Inc
29/01/202413:00Business WireJury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past RoyaltiesNASDAQ:NTRANatera Inc
25/01/202413:00Business WireNature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal MalignanciesNASDAQ:NTRANatera Inc
22/01/202413:00Business WireNatera Acquires Reproductive Health Assets from InvitaeNASDAQ:NTRANatera Inc
22/01/202413:00PR Newswire (US)Invitae Completes Sale of Reproductive Health Assets to NateraNASDAQ:NTRANatera Inc
18/01/202414:00Business WireNatera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRCNASDAQ:NTRANatera Inc
16/01/202423:17Business WireNatera Provides Update on Ravgen TrialNASDAQ:NTRANatera Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NTRA

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BAMI
Banco BPM
BIT
SPM
Saipem
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
CPR
Davide Campari
BIT
G
Generali
BIT
TIT
Telecom Italia
BIT
FBK
Finecobank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network